论文部分内容阅读
Post-transplant lymphoproliferative disorder(PTLD),arare disease,is characterized by an abnormalproliferation of lymphoid cells after solid organtransplantation.~1 This complication is usually caused bythe immunosuppressive therapy following transplantation.Though the techniques of early detection and diagnosis ofthe disease are well established,treatment is not sostraightforward and poses a real challenge.At this time,options include anti-viral therapy,cytotoxicchemotherapy,cellular immunotherapy,and reduction ofimmunosuppression.But the effects of these therapies arenot satisfying.Rimximab,a chimeric monoclonalanti-CD20 antibody used for the treatment of B celllymphoma with a good effect,is rarely,especially in
Post-transplant lymphoproliferative disorder (PTLD), arare disease, is characterized by an abnormalproliferation of lymphoid cells after solid organtransplantation. ~ 1 This complication is usually caused by the immunosuppressive therapy following transplantation. Hough the techniques of early detection and diagnosis of the the disease are well established , treatment is not sostraightforward and poses a real challenge. At this time, options include anti-viral therapy, cytotoxic chemotherapy, cellular immunotherapy, and reduction of immunosuppression. But the effects of these therapies arenot satisfied.Rimximab, a chimeric monoclonalanti-CD20 antibody used for the treatment of B celllymphoma with a good effect, is rarely, especially in